Drugs / NX-5948
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06717269 | Nov 2024 → Apr 2026 overdue | — | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06691828 | Nov 2024 | — | Nurix Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06593457 | Aug → Oct 2024 | — | Nurix Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05131022 | Apr 2022 → Jan 2027 expected | Waldenstrom macroglobulinemia, central nervous system non-hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +3 | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07520006 | May 2026 → May 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07221500 | Oct 2025 → Jan 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07516093 | Aug 2026 → Oct 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Nurix Therapeutics, Inc. | Results Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy nurixtx.com ↗
today announced updated clinical data from the Company’s ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). |
| 2026-05-14 | Nurix Therapeutics, Inc. | Results Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting nurixtx.com ↗
The findings demonstrate that targeted degradation of BTK may provide broader and deeper suppression of pathogenic immune signaling than BTK inhibition alone, supporting the future clinical development of bexobrutideg in inflammation and immunology indications. |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX-5948 | “NX-5948 oral” NCT06593457 ↗ |
| Known as | BTK-IN-24 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5558927 ↗ |
| Action | Inhibit | “NX-5948 is a BTK degrader and works by destroying the BTK protein to stop all its actions.” NCT07221500 ↗ |
| Modality | Other / unclassified | “a Bruton's Tyrosine Kinase (BTK) Degrader” NCT05131022 ↗ |
| Route | Oral | “Oral NX-5948” NCT05131022 ↗ |
| Target | BTK | “a Bruton's Tyrosine Kinase (BTK) Degrader” NCT05131022 ↗ |